SCHEMBL1642053

SCHEMBL1642053

O=C(Nc1ccccc1)c1cn(Cc2ccccc2)c(=O)cc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
RAB9A P51151 2/20 0.59
ALDH1A1 P00352 2/20 0.56
POLB P06746 2/20 0.51
KDM4E B2RXH2 2/20 0.50
HTT P42858 2/20 0.50
RXFP1 Q9HBX9 1/20 0.48
TMPRSS4 Q9NRS4 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TP53 P04637 2/20 0.48
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
FSCN1 Q16658 1/20 0.47
BRD4 O60885 2/20 0.47
BRD2 P25440 1/20 0.47
BRD3 Q15059 1/20 0.47
BRDT Q58F21 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641964 0.89 KDM4E (0.54) MAPTSMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL1640573 0.85 BRD4 (0.65) MAPTSMN1; SMN2RAB9AALDH1A1HTT
SCHEMBL1640326 0.84 HSP90AA1 (0.58) MAPTSMN1; SMN2ALDH1A1KDM4EHTT
SCHEMBL1642063 0.83 KDR (0.56) MAPTSMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL1640352 0.83 LMNA (0.55) MAPTSMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL1641962 0.83 NPC1 (0.54) MAPTSMN1; SMN2RAB9AALDH1A1POLB
SCHEMBL1640848 0.82 CNR2 (0.50) MAPTRAB9AALDH1A1KDM4EMEN1
SCHEMBL1641827 0.82 BRD4 (0.57) MAPTMEN1KMT2ABRD4BRD2
SCHEMBL1642389 0.81 EGLN1 (0.48) SMN1; SMN2RAB9AALDH1A1HTTBRD4
SCHEMBL1640452 0.81 ALDH1A1 (0.53) MAPTSMN1; SMN2RAB9AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2306828-A1 PROLYL HYDROXYLASE INHIBITORS Glaxosmithkline LLC (US) 2011-04-13 EP disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 MAPT 4716/4885SMN1; SMN2 3631/4885RAB9A 4079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.